Ceragenix Pharmaceuticals

Ceragenix loses almost $13M in 2005
Denver Business Journal - Ceragenix Pharmaceuticals Inc. lost nearly $13 million last year, the company announced Monday. The Denver company (OTCBB: CGXP), which doesn't have any revenue yet, has lost $13.8 million since 2002. During 2004, the company posted a net loss of

business Colorado business, 4/13
Denver Post - Apex Silver Mines Limited announced Wednesday it has completed its previously announced offering of 6.4 million shares of stock at $24.45 per share. Apex Silver intends to use the net proceeds of about $151 million to continue further evaluation

Latest News
dBusinessNews.com - Denver: Avian Influenza Pandemic Operational Continuity Training Now Available Online From NexPort Solutions and NEHA DENVER -- NexPort Solutions and the National Environmental Health Association Denver: Ceragenix Pharmaceuticals to Present at

FDA Approvals: Integrated Insulin Pump/Glucose Monitoring System
Medscape News - April 18, 2006 The US Food and Drug Administration (FDA) has approved an integrated insulin pump and continuous glucose monitoring system for the management of type 1 and type 2 diabetes mellitus; 3 fetoscopy instrument sets for the treatment of

Ceragenix Receives 510k Clearance of EpiCeram(R) for the Treatment of
Genetic Engineering News - Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced it has received 510K clearance from the U.S. Food and Drug Administration ("FDA") for its EpiCeram(R) Skin Barrier Emulsion to